Free Newsletter
Lilly execs pull down $48M
It's that time of year again: CEO salary time, when we gather round the water cooler to ooh and ahh over our bosses' paychecks. Today, it's Eli Lilly workers who'll have that privilege, thanks to the Indianapolis Star. The top six execs at Lilly garnered $48 million in pay last year, the Star reports.
Who got a raise? CEO John Lechleiter (photo), for one; he took in $13 million last year, up 39 percent from 2007. Of that, $1.34 million was base salary, which bumped up by 17 percent from last year. And he's been CEO only since April. Chairman emeritus Sidney Taurel (photo) also got $13 million, in addition to the $40 million retirement package that awaits him.
Lilly's board gave Lechleiter credit for snatching ImClone Systems out from under Bristol-Myers Squibb's nose in a $6.3 billion buyout. Directors also praised him for the company's operational results: sales grew 9 percent to $18.6 billion, and though the company posted a $2.07 billion loss, that was largely because of ImClone acquisition expenses.
- see the BNet Pharma story
- get more from the Indianapolis Star
- read the AP story on Taurel's retirement
Related Articles:
CEO Pay: Who makes what in Big Biotech?
Top paychecks in Big Pharma
Eli Lilly and ImClone - Top 10 deals of 2008
Eli Lilly - Biotech market share report
Lilly's Lechleiter: 'We're a biotech'
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: